Janney Montgomery Scott LLC Has $1.52 Million Stock Holdings in STERIS plc (NYSE:STE)

Janney Montgomery Scott LLC trimmed its holdings in shares of STERIS plc (NYSE:STE) by 2.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,403 shares of the medical equipment provider’s stock after selling 206 shares during the quarter. Janney Montgomery Scott LLC’s holdings in STERIS were worth $1,522,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. AQR Capital Management LLC raised its holdings in shares of STERIS by 29.1% during the second quarter. AQR Capital Management LLC now owns 15,094 shares of the medical equipment provider’s stock worth $3,276,000 after acquiring an additional 3,398 shares during the period. NewEdge Advisors LLC raised its stake in shares of STERIS by 22.9% in the 2nd quarter. NewEdge Advisors LLC now owns 5,139 shares of the medical equipment provider’s stock valued at $1,128,000 after purchasing an additional 956 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of STERIS by 7.6% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,040 shares of the medical equipment provider’s stock valued at $448,000 after purchasing an additional 144 shares in the last quarter. Cetera Investment Advisers lifted its holdings in shares of STERIS by 8.2% in the second quarter. Cetera Investment Advisers now owns 13,343 shares of the medical equipment provider’s stock valued at $2,930,000 after purchasing an additional 1,013 shares in the last quarter. Finally, Sanctuary Advisors LLC acquired a new position in shares of STERIS during the second quarter worth about $1,751,000. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at STERIS

In other STERIS news, SVP Cary L. Majors sold 1,682 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $217.32, for a total value of $365,532.24. Following the transaction, the senior vice president now directly owns 11,372 shares of the company’s stock, valued at $2,471,363.04. This represents a 12.88 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.14% of the stock is currently owned by corporate insiders.

STERIS Stock Performance

NYSE STE opened at $218.23 on Tuesday. The firm has a market capitalization of $21.54 billion, a P/E ratio of 49.82 and a beta of 0.84. The company has a current ratio of 2.41, a quick ratio of 1.55 and a debt-to-equity ratio of 0.33. The firm’s fifty day moving average price is $212.15 and its two-hundred day moving average price is $224.70. STERIS plc has a 1 year low of $197.82 and a 1 year high of $248.24.

STERIS (NYSE:STE) last issued its earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.12 by $0.02. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The company had revenue of $1.33 billion for the quarter, compared to analysts’ expectations of $1.33 billion. During the same period in the prior year, the firm earned $2.03 EPS. STERIS’s quarterly revenue was up 7.3% compared to the same quarter last year. As a group, research analysts anticipate that STERIS plc will post 9.11 EPS for the current year.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 21st. Stockholders of record on Thursday, February 20th will be given a $0.57 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.04%. STERIS’s payout ratio is 52.05%.

Analyst Ratings Changes

Several equities research analysts have commented on STE shares. JMP Securities restated a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a research note on Monday, November 18th. Stephens reissued an “overweight” rating and issued a $260.00 price objective on shares of STERIS in a research report on Thursday, November 7th. StockNews.com downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 29th. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research report on Friday, November 8th. Finally, Piper Sandler increased their price objective on shares of STERIS from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $263.75.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.